Teresa Raquel Andrade1, Jorge Ibrain Figueira Salluh2, Raphaela Garcia1, Daniela Farah1, Paulo Sérgio Lucas da Silva3, Danielle F Bastos4, Marcelo Cunio Machado Fonseca5. 1. AxiaBio Life Sciences International Ltda. - São Paulo (SP), Brasil. 2. Instituto D'Or de Pesquisa e Ensino - Rio de Janeiro (RJ), Brasil. 3. Unidade de Terapia Intensiva Pediátrica, Departamento de Pediatria, Hospital do Servidor Público Municipal - São Paulo (SP), Brasil. 4. Aspen Pharma - São Paulo (SP), Brasil. 5. Departamento de Ginecologia, Núcleo de Avaliação de Tecnologias em Saúde, Universidade Federal de São Paulo - São Paulo (SP), Brasil.
Abstract
OBJECTIVE: To build a cost-effectiveness model to compare the use of propofol versus midazolam in critically ill adult patients under mechanical ventilation. METHODS: We built a decision tree model for critically ill patients submitted to mechanical ventilation and analyzed it from the Brazilian private health care system perspective. The time horizon was that of intensive care unit hospitalization. The outcomes were cost-effectiveness per hour of intensive care unit stay avoided and cost-effectiveness per hour of mechanical ventilation avoided. We retrieved data for the model from a previous meta-analysis. We assumed that the cost of medication was embedded in the intensive care unit cost. We conducted univariate and probabilistic sensitivity analyses. RESULTS: Mechanically ventilated patients using propofol had their intensive care unit stay and the duration of mechanical ventilation decreased by 47.97 hours and 21.65 hours, respectively. There was an average cost reduction of US$ 2,998.971 for propofol when compared to midazolam. The cost-effectiveness per hour of intensive care unit stay and mechanical ventilation avoided were dominant 94.40% and 80.8% of the time, respectively. CONCLUSION: There was a significant reduction in costs associated with propofol use related to intensive care unit stay and duration of mechanical ventilation for critically ill adult patients.
OBJECTIVE: To build a cost-effectiveness model to compare the use of propofol versus midazolam in critically ill adult patients under mechanical ventilation. METHODS: We built a decision tree model for critically ill patients submitted to mechanical ventilation and analyzed it from the Brazilian private health care system perspective. The time horizon was that of intensive care unit hospitalization. The outcomes were cost-effectiveness per hour of intensive care unit stay avoided and cost-effectiveness per hour of mechanical ventilation avoided. We retrieved data for the model from a previous meta-analysis. We assumed that the cost of medication was embedded in the intensive care unit cost. We conducted univariate and probabilistic sensitivity analyses. RESULTS: Mechanically ventilated patients using propofol had their intensive care unit stay and the duration of mechanical ventilation decreased by 47.97 hours and 21.65 hours, respectively. There was an average cost reduction of US$ 2,998.971 for propofol when compared to midazolam. The cost-effectiveness per hour of intensive care unit stay and mechanical ventilation avoided were dominant 94.40% and 80.8% of the time, respectively. CONCLUSION: There was a significant reduction in costs associated with propofol use related to intensive care unit stay and duration of mechanical ventilation for critically ill adult patients.
Sedatives are frequently employed to improve mechanical ventilation comfort and
synchrony in critically ill patients.( The current Clinical Practice Guidelines for the Prevention and
Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption
in Adult Patients in the ICU (PADIS) recommend a sedation strategy that advise
against the use of benzodiazepines.( However, benzodiazepines are still commonly used, and in fact,
the most widely used sedative agents in critically ill adults are propofol and
midazolam.(Although midazolam is widely used, one of the main midazolam characteristics is its
lipophilic character, and this feature influences its metabolism, thus leading to
its accumulation in adipose tissues. In addition, midazolam is broken down into
active metabolites, which can be stored in the kidney. Such a cumulative effect may
play a role in prolonged weaning from mechanical ventilation, as patients present a
long time to awakening. Another concern is the increased risk of
delirium in patients sedated with midazolam and its long-term
consequences, such as postintensive care syndrome.(On the other hand, propofol, also a widely used sedative in the intensive care unit
(ICU), presents rapid onset of action in seconds, with a fast redistribution of the
drug to peripheral tissues. These properties allow a patient to quickly recover
consciousness after the discontinuation of propofol, even when it is administered
for prolonged periods. Hence, propofol in mechanically ventilated patients is
associated with a shorter time needed to recover spontaneous breathing.( Nonetheless, there is a perception
that propofol may have a higher cost than benzodiazepines.(Despite the clinical benefits of avoiding benzodiazepine use in mechanically
ventilated patients,( the
economic impact of this choice has not been thoroughly evaluated. Therefore, we
aimed to conduct an economic analysis to compare the use of propofol with the use of
midazolam in critically ill adult patients under mechanical ventilation admitted to
the ICU for over 24 hours.
METHODS
Model structure and population
We developed a decision-tree model to simulate propofol or midazolam
administration in critically ill adult patients (≥ 18 years) on
mechanical ventilation whose ICU stay exceeded 24 hours (Figure 1).
Figure 1
Decision analytical tree model.
ICU - intensive care unit; MV - mechanical ventilation.
Analysis perspective
The perspective of this analysis was the Brazilian supplementary health system
(private health system) for 2018.
Interventions in comparison
The evaluated interventions were two sedatives used in mechanically ventilated
patients admitted to the ICU. Propofol, a nonbenzodiazepine drug, and midazolam,
a benzodiazepine drug, were compared. In the table
1S (Supplementary material), we present the
analgesia management.Decision analytical tree model.ICU - intensive care unit; MV - mechanical ventilation.
Time horizon
The time horizon corresponds to the period of hospitalization in the ICU of the
studies incorporated in the meta-analysis previously carried out by this group.
In the studies included in this meta-analysis, the hospitalization period ranged
from 224 to 660 hours.(Since the time horizon was less than one year, we did not apply a discount
rate.
Clinical data and costs
The clinical data inputs were from a previously published
meta-analysis,( where
the use of propofol reduced ICU stays by 47.97 hours and mechanical ventilation
by 21.65 hours.We used the meta-analysis mean difference of ICU stay and the mean difference of
mechanical ventilation days to build the model. Thus, we did not have the number
of hours a patient was on mechanical ventilation or the number of hours a
patient spent in the ICU for the propofol or midazolam group. Only the time
difference between propofol and midazolam use was available for each of these
outcomes.The mean cost of one day in the ICU for a mechanically ventilated adult patient,
regardless of the ICU of hospitalization, was retrieved from an insurance
database in the state of São Paulo, Brazil.(We expressed values as US dollars (US$). The exchange rate in 2018 to convert
Brazilian reais (R$) into US dollars was US$1.00 equaled R$3.6552. The mean
total cost of one day in an ICU for a mechanically ventilated adult patient was
US$ 1,500.42.(To calculate the costs, the difference in ICU stay hours implied a cost
difference between the arms.The outcomes of interest evaluated in this model were cost-effectiveness per hour
of ICU stay avoided and cost-effectiveness per hour of mechanical ventilation
avoided.
Model assumptions
Our model assumed that the costs of the studied sedatives are included in the
patients’ total hospitalization cost. The private health plan database costs
represented the private market health costs in Brazil, and the cost of ICU stay
per day was the same in both arms.
Sensitivity analysis
We performed a univariate sensitivity analysis modifying one parameter of the
model at a time. Additionally, we carried out a probabilistic sensitivity
analysis through a Monte Carlo simulation of ten thousand interactions. In the
probabilistic sensitivity analysis, we varied several parameters at the same
time. The varied parameters with their respective ranges and references are
shown in table 1. We used Palisade @RISK
software to execute the sensitivity analyses.
Table 1
Values used in the sensitivity analysis
Parameter
Base value
Minimum
value
Maximum
value
Distribution
Reference
Difference in the
length of ICU stay (hours) (propofol - midazolam)
-47.97
18.46
-114.40
Normal
Meta-analysis(7)
Difference in the
mechanical ventilation time (hours) (propofol - midazolam)
-32.68
-22.06
-65.36
Normal
Meta-analysis(7)
Cost of ICU stay
per day (US$)
1,500.42
597.13
1,848.02
Log-normal
Database of
private plans in the state of São Paulo,
Brazil(8)
ICU - intensive care unit.
RESULTS
Base case
The use of propofol in critically ill patients requiring sedation by mechanical
ventilation resulted in a mean reduction of 47.97 hours in the length of ICU
stay and 21.65 hours in mechanical ventilation time and a mean decrease of US$
2,998.97 in the cost when compared to midazolam. Hence, the mean incremental
cost-effectiveness ratio (ICER) per hour of ICU stay avoided was US$62.52, and
the ICER per hour of mechanical ventilation avoided was US$138.52. Note that the
ICER was positive because both the cost and effectiveness differences were
negative.In the univariate sensitivity analysis, the parameter that most influenced the
cost-effectiveness per hour of ICU stay avoided was the daily cost. In contrast,
the parameter that most influenced the cost-effectiveness per hour of mechanical
ventilation avoided was ICU length of stay.The probabilistic sensitivity analysis for the cost-effectiveness per hour of ICU
stay avoided showed that most of the points (94.4%) were located in the third
quadrant of the graph, indicating lower costs and decreased length of ICU stay
when patients used propofol. Propofol was the dominant alternative (Figure 2).
Figure 2
Probabilistic sensitivity analysis for cost-effectiveness per hour of
avoided intensive care unit stay with 10,000 interactions.
Probabilistic sensitivity analysis for cost-effectiveness per hour of
avoided intensive care unit stay with 10,000 interactions.The probabilistic sensitivity analysis for the cost-effectiveness per hour of
mechanical ventilation avoided showed that most of the interactions (80.8%) were
in the third quadrant. In this quadrant, the costs and mechanical ventilation
duration are lower. Therefore, propofol was, again, the dominant alternative
(Figure 3).
Figure 3
Probabilistic sensitivity analysis for cost-effectiveness per hour of
avoided mechanical ventilation with 10,000 interactions.
Values used in the sensitivity analysisICU - intensive care unit.Probabilistic sensitivity analysis for cost-effectiveness per hour of
avoided mechanical ventilation with 10,000 interactions.
DISCUSSION
In 2018, the Society of Critical Care Medicine (SCCM) published the PADIS guidelines,
a revision of the guidelines that were previously published in 2013. In this most
current guideline, again, it is recommended that nonbenzodiazepine drugs should be
used instead of benzodiazepines for the sedation of patients on mechanical
ventilation.As the recommendation is conditional, it is crucial to determine the impact of the
use of nonbenzodiazepine drugs on health costs. To the best of our knowledge, no
other cost-effectiveness study has compared the sedation regimen using propofol with
the sedation regimen using midazolam.(Our group previously performed a systematic review followed by a meta-analysis
comparing the use of propofol (a nonbenzodiazepine) with that of midazolam (a
benzodiazepine).( Thus,
we built a simple decision tree based on the results of our previous study. This
study suggests that a propofol-based sedation regimen is cost-effective for sedation
in critically ventilated adults in the ICU compared to a midazolam-based sedation
regimen.The clinical differences in the length of stay in the ICU and the duration of
mechanical ventilation between the propofol and midazolam regimens incorporated in
the model came from the results of a meta-analysis of 23 controlled studies, unlike
a previous study whose data came from only two small controlled studies.(Our model, similar to other studies that compared sedation regimens with a
nonbenzodiazepine with sedation regimens with benzodiazepine, showed that using
propofol to sedate critically ill patients under mechanical ventilation is
predominately cost saving when compared to midazolam.( These
cost savings occur due to the reduced length of ICU stay and the duration of
mechanical ventilation. The cost-effectiveness for one hour of ICU stay avoided and
for one hour of mechanical ventilation avoided were dominant 95% and 81% of the
time, respectively.The duration of mechanical ventilation is a critical patient-related outcome. In
patients hospitalized for more than 24 hours, prolonged use of mechanical
ventilation carries a greater risk of complications, especially
pneumonia.(
Ventilator-associated pneumonia (VAP) is a frequent and severe respiratory infection
that is often associated with high mortality rates.( In a Brazilian private health database, there
were 24 cases of VAP for every 1,000 hours under mechanical ventilation.( Therefore, based on the present
data, we estimated that propofol would reduce 520 cases of VAP in 10,000
patients.Cost-effectiveness analysis often presents potential limitations.( We consulted one database
representing only the state of São Paulo and assumed that the data were
representative of Brazil’s private health system. The drugs’ cost was included in
the daily cost of the ICU stay, and unfortunately, the database consulted did not
present the costs for the different drugs separately. Our study did not include the
costs associated with possible adverse events related to the drugs under
investigation, such as delirium or infection. On the other hand, an
adverse event related to these drugs would probably increase mechanical ventilation
duration, which would appear in the results.( We also did not incorporate in our model the daily
interruption of sedation or sedation guided by a nursing protocol that could
potentially reduce the duration of mechanical ventilation.( Finally, as we only evaluated
costs related to hospital admission, we could not capture the potential long term
effects. This limitation is relevant because prolonged mechanical ventilation and
the use of benzodiazepines were associated with the occurrence of
delirium and postintensive care syndrome, both with a high
impact on long-term morbidity, health-related costs, and mortality.(
CONCLUSION
From the perspective of the Brazilian private health system, the use of propofol as
the first choice sedative for critically ill adult patients treated in the intensive
care unit and who need mechanical ventilation for more than 24 hours proved to be
cost-saving due to its capacity to reduce the length of intensive care unit stay and
the duration of mechanical ventilation. Our results are consistent with the PADIS
guidelines of using nonbenzodiazepine drugs for sedation in critically ill,
mechanically ventilated adults.
Authors: William F McGhan; Maiwenn Al; Jalpa A Doshi; Isao Kamae; Steven E Marx; Donna Rindress Journal: Value Health Date: 2009-09-10 Impact factor: 5.725
Authors: John W Devlin; Yoanna Skrobik; Céline Gélinas; Dale M Needham; Arjen J C Slooter; Pratik P Pandharipande; Paula L Watson; Gerald L Weinhouse; Mark E Nunnally; Bram Rochwerg; Michele C Balas; Mark van den Boogaard; Karen J Bosma; Nathaniel E Brummel; Gerald Chanques; Linda Denehy; Xavier Drouot; Gilles L Fraser; Jocelyn E Harris; Aaron M Joffe; Michelle E Kho; John P Kress; Julie A Lanphere; Sharon McKinley; Karin J Neufeld; Margaret A Pisani; Jean-Francois Payen; Brenda T Pun; Kathleen A Puntillo; Richard R Riker; Bryce R H Robinson; Yahya Shehabi; Paul M Szumita; Chris Winkelman; John E Centofanti; Carrie Price; Sina Nikayin; Cheryl J Misak; Pamela D Flood; Ken Kiedrowski; Waleed Alhazzani Journal: Crit Care Med Date: 2018-09 Impact factor: 7.598
Authors: R Barrientos-Vega; M Mar Sánchez-Soria; C Morales-García; A Robas-Gómez; R Cuena-Boy; A Ayensa-Rincon Journal: Crit Care Med Date: 1997-01 Impact factor: 7.598
Authors: Timothy D Girard; John P Kress; Barry D Fuchs; Jason W W Thomason; William D Schweickert; Brenda T Pun; Darren B Taichman; Jan G Dunn; Anne S Pohlman; Paul A Kinniry; James C Jackson; Angelo E Canonico; Richard W Light; Ayumi K Shintani; Jennifer L Thompson; Sharon M Gordon; Jesse B Hall; Robert S Dittus; Gordon R Bernard; E Wesley Ely Journal: Lancet Date: 2008-01-12 Impact factor: 79.321